文献速递妇科

OVATION-2:IMNN-001(IL-12基因治疗)联合新辅助/辅助化疗治疗新诊断晚期上皮性卵巢癌的随机I/II期研究

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-06-03

OVATION-2是一项随机对照开放标签I/II期研究,评估IMNN-001(IL-12免疫基因治疗)联合新辅助/辅助化疗对比单纯化疗在新诊断晚期上皮性卵巢癌(EOC)中的安全性和疗效。实验组54例、对照组58例,主要终点为安全性和无进展生存期(PFS)。实验组耐受性良好,PFS 14.9个月 vs 11.9个月(HR 0.79,95%CI 0.51-1.23),总生存期(OS)46.0个月 vs 33.0个月(HR 0.69,95%CI 0.40-1.19)。

要点

  • IMNN-001联合化疗耐受性良好,最常见TEAE为胃肠道反应和血细胞减少,无细胞因子释放综合征(CRS)或免疫事件风险升高。
  • 实验组PFS 14.9个月 vs 对照组11.9个月(HR 0.79,95%CI 0.51-1.23);OS 46.0个月 vs 33.0个月(HR 0.69,95%CI 0.40-1.19)。
  • 接受PARPi维持治疗患者中,实验组PFS 33.8个月 vs 22.1个月(HR 0.80,95%CI 0.31-2.12),OS未达到 vs 37.1个月(HR 0.38,95%CI 0.13-1.06)。

核心结论

  • 在新诊断晚期上皮性卵巢癌患者中,IMNN-001联合新辅助/辅助化疗显示出有前景的数值上13个月的生存获益,且安全性可接受。

研究设计与样本

  • 随机、对照、开放标签I/II期研究,高级别上皮性卵巢癌患者按1:1随机分组。
  • 对照组接受卡铂/紫杉醇静脉化疗每21天3周期,间隔减瘤手术(IDS)前后各给药;实验组接受腹腔内IMNN-001每周给药,与化疗同步,IDS前8周和IDS后9周。
  • 实验组54例、对照组58例,以IIIC/IV期EOC为主。
  • 主要终点为安全性和无进展生存期(PFS)。

主要发现

  • 实验组总体耐受性良好,最常见TEAE为胃肠道反应和血细胞减少,无CRS或免疫事件风险升高。
  • PFS:实验组14.9个月 vs 对照组11.9个月;HR 0.79(95%CI 0.51-1.23)。
  • OS:实验组46.0个月 vs 对照组33.0个月;HR 0.69(95%CI 0.40-1.19)。
  • 手术R0率:实验组64.6% vs 对照组52.1%。
  • 接受PARPi维持治疗患者中,PFS:实验组33.8个月 vs 对照组22.1个月;HR 0.80(95%CI 0.31-2.12);OS:实验组未达到 vs 对照组37.1个月;HR 0.38(95%CI 0.13-1.06),均倾向于实验组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: OVATION-2, a randomized, controlled, open label phase 1/2 study, evaluated the safety and efficacy of IMNN-001, an IL-12 immune gene therapy, with neo/adjuvant chemotherapy (N/ACT) compared to N/ACT in newly-diagnosed advanced epithelial ovarian cancer (EOC). METHODS: IMNN-001 is an immunotherapeutic nanoparticle comprising a DNA plasmid encoding the IL-12 gene encased in a lipopolymer. High-grade EOC patients were randomized 1:1 to carboplatin/paclitaxel IV every 21 days for 3 cycles, before and after interval debulking surgery (IDS) or to intraperitoneal (IP) IMNN-001, given weekly concurrently with chemotherapy for 8 weeks before and 9 weeks after IDS. RESULTS: 54 and 58 patients with predominantly Stage IIIC/IV EOC were evaluated in the control and experimental arm, respectively. Primary endpoints were safety and PFS. Overall, the experimental arm was well tolerated with gastrointestinal and cytopenias as the most common TEAEs with no CRS or elevated risk of immune events. PFS was 14.9 months (mo) for the experimental arm vs 11.9 mo; HR 0.79 (95 % CI: 0.51-1.23). Secondary endpoints included OS (46.0 mo for experimental arm vs 33.0 mo; HR 0.69 (CI: 0.40-1.19)) and surgical response R0 rate (64.6 % experimental arm vs 52.1 %). For patients who received PARPi maintenance, PFS was 33.8 mo vs 22.1 mo; HR 0.80 (CI: 0.31-2.12) and OS was NE vs 37.1 mo with a HR of 0.38 (CI: 0.13-1.06) both favoring the experimental arm. CONCLUSION: The addition of IMNN-001 to N/ACT shows a promising numerical 13-mo benefit on survival with an acceptable safety profile in patients with newly-diagnosed advanced EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Thaker PH, Richardson DL, Hagemann AR, et al. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer. Gynecol Oncol. 2025. PMID: 40461366. doi:10.1016/j.ygyno.2025.04.578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。